Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival

Vincent P. Groot, Alex B. Blair, Georgios Gemenetzis, Ding Ding, Richard Burkhart, A. Floortje van Oosten, I. Quintus Molenaar, John L Cameron, Matthew J Weiss, Stephen C Yang, Christopher Wolfgang, Jin He

Research output: Contribution to journalArticle

Abstract

Background: The literature suggests favorable survival for patients with isolated pulmonary recurrence after resection of pancreatic ductal adenocarcinoma (PDAC) as compared to other recurrence patterns. Within this cohort, it remains unclear what factors are associated with improved survival. Methods: Patients who developed pulmonary recurrence after pancreatectomy were selected from a prospective database. Predictors for post-recurrence survival (PRS) were analyzed using a multivariable Cox regression model. Results: Ninety-six patients were included. Median recurrence-free survival (RFS), PRS and overall survival (OS) were 16.3, 18.8 and 39.6 months, respectively. Further systemic treatment and/or metastasectomy (n = 64, 67%) was associated with significantly improved PRS and OS when compared to best supportive care (n = 35, 22%) (26.3 vs. 5.3 and 48.1 vs. 18.4, respectively; both P < 0.001). Patients who were able to undergo metastasectomy (n = 19) achieved a PRS and OS of 35.0 and 68.9 months, respectively. More than 5 pulmonary lesions, symptoms and CA 19-9 ≥100 U/mL at time of recurrence were predictive of decreased PRS. A recurrence-free interval of >16 months and treatment for recurrence were independently associated with improved PRS. Conclusions: Isolated pulmonary recurrence occurs in 13% of patients with recurrent PDAC and is associated with a median OS of 40 months. Aggressive treatment in highly selected patients was correlated with improved survival.

Original languageEnglish (US)
JournalHPB
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pancreatic Neoplasms
Recurrence
Lung
Survival
Therapeutics
Adenocarcinoma
Metastasectomy
Pancreatectomy
Proportional Hazards Models
Databases

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Isolated pulmonary recurrence after resection of pancreatic cancer : the effect of patient factors and treatment modalities on survival. / Groot, Vincent P.; Blair, Alex B.; Gemenetzis, Georgios; Ding, Ding; Burkhart, Richard; van Oosten, A. Floortje; Molenaar, I. Quintus; Cameron, John L; Weiss, Matthew J; Yang, Stephen C; Wolfgang, Christopher; He, Jin.

In: HPB, 01.01.2019.

Research output: Contribution to journalArticle

Groot, Vincent P. ; Blair, Alex B. ; Gemenetzis, Georgios ; Ding, Ding ; Burkhart, Richard ; van Oosten, A. Floortje ; Molenaar, I. Quintus ; Cameron, John L ; Weiss, Matthew J ; Yang, Stephen C ; Wolfgang, Christopher ; He, Jin. / Isolated pulmonary recurrence after resection of pancreatic cancer : the effect of patient factors and treatment modalities on survival. In: HPB. 2019.
@article{1f34672f95a04cd697d4769b91ddfb13,
title = "Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival",
abstract = "Background: The literature suggests favorable survival for patients with isolated pulmonary recurrence after resection of pancreatic ductal adenocarcinoma (PDAC) as compared to other recurrence patterns. Within this cohort, it remains unclear what factors are associated with improved survival. Methods: Patients who developed pulmonary recurrence after pancreatectomy were selected from a prospective database. Predictors for post-recurrence survival (PRS) were analyzed using a multivariable Cox regression model. Results: Ninety-six patients were included. Median recurrence-free survival (RFS), PRS and overall survival (OS) were 16.3, 18.8 and 39.6 months, respectively. Further systemic treatment and/or metastasectomy (n = 64, 67{\%}) was associated with significantly improved PRS and OS when compared to best supportive care (n = 35, 22{\%}) (26.3 vs. 5.3 and 48.1 vs. 18.4, respectively; both P < 0.001). Patients who were able to undergo metastasectomy (n = 19) achieved a PRS and OS of 35.0 and 68.9 months, respectively. More than 5 pulmonary lesions, symptoms and CA 19-9 ≥100 U/mL at time of recurrence were predictive of decreased PRS. A recurrence-free interval of >16 months and treatment for recurrence were independently associated with improved PRS. Conclusions: Isolated pulmonary recurrence occurs in 13{\%} of patients with recurrent PDAC and is associated with a median OS of 40 months. Aggressive treatment in highly selected patients was correlated with improved survival.",
author = "Groot, {Vincent P.} and Blair, {Alex B.} and Georgios Gemenetzis and Ding Ding and Richard Burkhart and {van Oosten}, {A. Floortje} and Molenaar, {I. Quintus} and Cameron, {John L} and Weiss, {Matthew J} and Yang, {Stephen C} and Christopher Wolfgang and Jin He",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.hpb.2018.12.002",
language = "English (US)",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Isolated pulmonary recurrence after resection of pancreatic cancer

T2 - the effect of patient factors and treatment modalities on survival

AU - Groot, Vincent P.

AU - Blair, Alex B.

AU - Gemenetzis, Georgios

AU - Ding, Ding

AU - Burkhart, Richard

AU - van Oosten, A. Floortje

AU - Molenaar, I. Quintus

AU - Cameron, John L

AU - Weiss, Matthew J

AU - Yang, Stephen C

AU - Wolfgang, Christopher

AU - He, Jin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The literature suggests favorable survival for patients with isolated pulmonary recurrence after resection of pancreatic ductal adenocarcinoma (PDAC) as compared to other recurrence patterns. Within this cohort, it remains unclear what factors are associated with improved survival. Methods: Patients who developed pulmonary recurrence after pancreatectomy were selected from a prospective database. Predictors for post-recurrence survival (PRS) were analyzed using a multivariable Cox regression model. Results: Ninety-six patients were included. Median recurrence-free survival (RFS), PRS and overall survival (OS) were 16.3, 18.8 and 39.6 months, respectively. Further systemic treatment and/or metastasectomy (n = 64, 67%) was associated with significantly improved PRS and OS when compared to best supportive care (n = 35, 22%) (26.3 vs. 5.3 and 48.1 vs. 18.4, respectively; both P < 0.001). Patients who were able to undergo metastasectomy (n = 19) achieved a PRS and OS of 35.0 and 68.9 months, respectively. More than 5 pulmonary lesions, symptoms and CA 19-9 ≥100 U/mL at time of recurrence were predictive of decreased PRS. A recurrence-free interval of >16 months and treatment for recurrence were independently associated with improved PRS. Conclusions: Isolated pulmonary recurrence occurs in 13% of patients with recurrent PDAC and is associated with a median OS of 40 months. Aggressive treatment in highly selected patients was correlated with improved survival.

AB - Background: The literature suggests favorable survival for patients with isolated pulmonary recurrence after resection of pancreatic ductal adenocarcinoma (PDAC) as compared to other recurrence patterns. Within this cohort, it remains unclear what factors are associated with improved survival. Methods: Patients who developed pulmonary recurrence after pancreatectomy were selected from a prospective database. Predictors for post-recurrence survival (PRS) were analyzed using a multivariable Cox regression model. Results: Ninety-six patients were included. Median recurrence-free survival (RFS), PRS and overall survival (OS) were 16.3, 18.8 and 39.6 months, respectively. Further systemic treatment and/or metastasectomy (n = 64, 67%) was associated with significantly improved PRS and OS when compared to best supportive care (n = 35, 22%) (26.3 vs. 5.3 and 48.1 vs. 18.4, respectively; both P < 0.001). Patients who were able to undergo metastasectomy (n = 19) achieved a PRS and OS of 35.0 and 68.9 months, respectively. More than 5 pulmonary lesions, symptoms and CA 19-9 ≥100 U/mL at time of recurrence were predictive of decreased PRS. A recurrence-free interval of >16 months and treatment for recurrence were independently associated with improved PRS. Conclusions: Isolated pulmonary recurrence occurs in 13% of patients with recurrent PDAC and is associated with a median OS of 40 months. Aggressive treatment in highly selected patients was correlated with improved survival.

UR - http://www.scopus.com/inward/record.url?scp=85061584548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061584548&partnerID=8YFLogxK

U2 - 10.1016/j.hpb.2018.12.002

DO - 10.1016/j.hpb.2018.12.002

M3 - Article

C2 - 30777697

AN - SCOPUS:85061584548

JO - HPB

JF - HPB

SN - 1365-182X

ER -